Is COPD up or down today?
COPD is up 0.37% today, last at 267.38. This stock moved +0.37% versus the prior close.
COPD · COPD
COPD (COPD) is trading at 267.38, up 0.37% on the session. COPD sits at the 50% mark of its 52-week range, carries a 14-day RSI of 51, and trades above its 50-day average. Over the past month it is up 1.54%.
Leading the coverage: “Mabwell's 9MW1911 Cuts COPD Exacerbations in Phase 1b/2a Trial - BioPharm International” (Google News Company, 4d ago). COPD is -2.50% since story.
COPD trades on a trailing P/E of 15.8 and is running 2.48% ahead of the S&P 500 over the same stretch.
Analyst firms are mostly reiterating — no strong directional shift lately.
COPD is up 0.37% today, last at 267.38. This stock moved +0.37% versus the prior close.
Leading the coverage: “Mabwell's 9MW1911 Cuts COPD Exacerbations in Phase 1b/2a Trial - BioPharm International” (Google News Company, 4d ago). COPD is -2.50% since story. Dominant story: New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show - ABC News - Breaking News, Latest News and Videos (1 source, neutral) RSI is 51 — neutral Price above 50-day average — short-term uptrend Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Loaded: Mar 2026 – Sep 2026 (181 days) · Drag or scroll left for earlier dates
New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show - ABC News - Breaking News, Latest News and Videos
AstraZeneca's Tozorakimab Shows Promise in COPD Trials, Stock Po - GuruFocus
AstraZeneca Reports Late-Stage Trial Success for COPD Drug in US - SuaraGarut.ID
AstraZeneca drug cuts COPD flare-ups in full data - Briefs Finance
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show - The American Journal of Managed Care